Takip et
Elizabeth Coker
Elizabeth Coker
AstraZeneca, Cambridge
astrazeneca.com üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Effective drug combinations in breast, colon and pancreatic cancer cells
P Jaaks, EA Coker, DJ Vis, O Edwards, EF Carpenter, SM Leto, L Dwane, ...
Nature 603 (7899), 166-173, 2022
3222022
canSAR: an updated cancer research and drug discovery knowledgebase
JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ...
Nucleic acids research 44 (D1), D938-D943, 2016
1112016
canSAR: updated cancer research and drug discovery knowledgebase
KC Bulusu, JE Tym, EA Coker, AC Schierz, B Al-Lazikani
Nucleic acids research 42 (D1), D1040-D1047, 2014
1052014
canSAR: update to the cancer translational research and drug discovery knowledgebase
C Mitsopoulos, P Di Micco, EV Fernandez, D Dolciami, E Holt, IL Mica, ...
Nucleic acids research 49 (D1), D1074-D1082, 2021
962021
Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens
E Gonçalves, A Segura‐Cabrera, C Pacini, G Picco, FM Behan, P Jaaks, ...
Molecular Systems Biology 16 (7), e9405, 2020
912020
canSAR: update to the cancer translational research and drug discovery knowledgebase
EA Coker, C Mitsopoulos, JE Tym, A Komianou, C Kannas, P Di Micco, ...
Nucleic acids research 47 (D1), D917-D922, 2019
642019
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
C Winkler, J Armenia, GN Jones, L Tobalina, MJ Sale, T Petreus, T Baird, ...
British journal of cancer 124 (5), 951-962, 2021
602021
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
SB Balachander, SW Criscione, KF Byth, J Cidado, A Adam, P Lewis, ...
Clinical Cancer Research 26 (24), 6535-6549, 2020
572020
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
S Dunn, C Eberlein, J Yu, A Gris-Oliver, SH Ong, U Yelland, N Cureton, ...
Oncogene 41 (46), 5046-5060, 2022
202022
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor …
V Flemington, EJ Davies, D Robinson, LC Sandin, O Delpuech, P Zhang, ...
Molecular cancer therapeutics 20 (2), 238-249, 2021
192021
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
A Stewart, EA Coker, S Pölsterl, A Georgiou, AR Minchom, S Carreira, ...
Molecular cancer therapeutics 18 (8), 1396-1404, 2019
182019
Large-scale pan-cancer cell line screening identifies actionable and effective drug combinations
AC Bashi, EA Coker, KC Bulusu, P Jaaks, C Crafter, H Lightfoot, M Milo, ...
Cancer discovery 14 (5), 846-865, 2024
122024
Individualized prediction of drug response and rational combination therapy in NSCLC using artificial intelligence–enabled studies of acute phosphoproteomic changes
EA Coker, A Stewart, B Ozer, A Minchom, L Pickard, R Ruddle, S Carreira, ...
Molecular cancer therapeutics 21 (6), 1020-1029, 2022
112022
SiGNet: A signaling network data simulator to enable signaling network inference
EA Coker, C Mitsopoulos, P Workman, B Al-Lazikani
Plos one 12 (5), e0177701, 2017
62017
Leveraging human genetics to guide cancer drug development
B Kinnersley, A Sud, EA Coker, JE Tym, P Di Micco, B Al-Lazikani, ...
JCO clinical cancer informatics 2, 1-11, 2018
52018
A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level
DJ Vis, P Jaaks, N Aben, EA Coker, S Barthorpe, A Beck, C Hall, J Hall, ...
Cell Reports Medicine 5 (8), 2024
32024
Simulated ablation for detection of cells impacting paracrine signalling in histology analysis
JP Taylor–King, E Baratchart, A Dhawan, EA Coker, IH Rye, H Russnes, ...
Mathematical Medicine and Biology: a Journal of the IMA 36 (1), 93-112, 2019
22019
Abstract B096: canSAR, a cancer research and drug discovery knowledgebase
EA Coker, P Di Micco, JE Tym, C Mitsopoulos, A Komianou, AA Antolin, ...
Molecular Cancer Therapeutics 17 (1_Supplement), B096-B096, 2018
22018
AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER
E Coker, A Emery, M Garnett, P Jaaks, H Lightfoot, JD Santos, D Vis, ...
US Patent App. 18/836,940, 2025
2025
Large scale pan cancer drug combination screening to identify effective and actionable combinations and biomarker hypothesis
A Bashi, EA Coker, K Bulusu, M Milo, C Crafter, J Lynch, D Jenkins, ...
Cancer Research 83 (7_Supplement), 5321-5321, 2023
2023
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20